Apomorphine subcutaneous infusion is an effective treatment for Parkinson patients whose motor fluctuations are poorly controlled by conventional therapies. This was shown by the large-scale TOLEDO ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

Credit: Thinkstock. SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump. The Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act ...

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

The benefits of the dopamine agonist apomorphine in Parkinson's disease have finally been confirmed in a randomized controlled trial, although the drug has been used in the condition for many years.

ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of ...

Results from the first randomized, controlled trial investigating the efficacy and safety of APO-go ® /MOVAPO ® (apomorphine) subcutaneous infusion in Parkinson's disease (PD) patients whose motor ...

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...

Please provide your email address to receive an email when new articles are posted on . Apomorphine may provide relief for patients with Parkinson’s disease during periods of immobility related to ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease ONAPGO is a wearable subcutaneous infusion ...